To examine the national drug discontinuation panel in Brazil to characterize the extent and patterns of medicine discontinuation, determine the principal underlying reasons, and evaluate which medicines have been most affected, while considering the potential risk of shortages.
Approach:
Study Design: Quantitative, observational, retrospective design using a publicly available secondary database from ANVISA's medicine-discontinuation panel for the years 2014–2024.
Data Analysis: Data included notifications regarding interruptions and resumptions of medicine manufacturing and importation, capturing regulatory classifications and reported circumstances surrounding discontinuations.
Statistical Methods: Annual percentage of market discontinuations calculated relative to the total pharmaceuticals commercialized nationally.
Key Findings:
Medicine shortages interrupt continuity of care and undermine therapeutic outcomes.
Brazil relies primarily on monitoring drug discontinuations rather than shortages.
The study identifies specific patterns and reasons for medicine discontinuation in Brazil.
Interpretation:
The findings indicate a need for integrated prevention and response policies in Brazil's pharmaceutical supply chain, as evidenced by the identified patterns of discontinuation.
Limitations:
The study is limited to data from ANVISA's discontinuation panel and may not capture all factors influencing medicine availability, particularly those not reported.
Data for 2014 was unavailable, and using 2015 as a proxy may affect the accuracy of trend analysis.
Conclusion:
Understanding patterns of medication discontinuation is crucial for addressing potential shortages and ensuring access to essential medicines in Brazil.
by Raphaella Oliveira Martins de Lima, Esther Ramos Silva, Isabel C. M. Emmerick, Danielle Maria de Souza Serio dos Santos, Isabella Piassi Dias Godói, Ana Cristina Viana Campos, Luisa Arueira Chaves
